Rhythmic data and 24h-Holter monitoring results
| Characteristics . | Patients . |
|---|---|
| Corrected QT on surface ECG (ms) | 416 ± 26 |
| Corrected QT > 440 ms, n (%) | 16 (16) |
| LVH criteria, n (%) | 19 (19) |
| Heart rate (bpm) | 72 ± 12 |
| Antiarrhythmic medication, n (%) | 38 (38) |
| Beta-blockers | 35 (35) |
| Cordarone | 5 (5) |
| Flecaine | 2 (2) |
| Indication for beta-blockers, n = 35, n (%) | |
| Antianginal | 4 (11) |
| Atrial hyperexcitability or AF | 21 (58) |
| Ventricular hyperexcitability | 5 (14) |
| Dilated heart disease | 11 (31) |
| LV obstruction | 3 (8) |
| Arterial hypertension | 2 (5) |
| 24h-Holter results | |
| Ventricular data | |
| Total PVCs | 11 (0-259), (min 0; max 12 809) |
| PVCs > 500/24 h, n (%) | 15 (15) |
| NSVT (<30 sec), n (%) | 9 (9); range, 4-121 PVCs |
| SVT (≥30 sec), n (%) | 0 (0) |
| Patients with VA, n (%) | 22 (22) |
| Total PVCs (n = 22) | 984 (452-4035) |
| PVC > 1000 (n = 22), n (%) | 11 (50) |
| PVC > 10 000 (n = 22), n (%) | 3 (13) |
| Polymorphic trait (≥2 families) (n = 22) | 18 (82) |
| Daytime predominance (n = 22) | 20 (91) |
| Ventricular hyperexcitability under beta-blocker (n = 22) | 8 (36) |
| Atrial data | |
| Total PACs | 35 (5-254), (min 0; max 24 270) |
| PACs > 500/24 h, n (%) | 17 (17) |
| Atrial fibrillation, n (%) | 3 (3) |
| Characteristics . | Patients . |
|---|---|
| Corrected QT on surface ECG (ms) | 416 ± 26 |
| Corrected QT > 440 ms, n (%) | 16 (16) |
| LVH criteria, n (%) | 19 (19) |
| Heart rate (bpm) | 72 ± 12 |
| Antiarrhythmic medication, n (%) | 38 (38) |
| Beta-blockers | 35 (35) |
| Cordarone | 5 (5) |
| Flecaine | 2 (2) |
| Indication for beta-blockers, n = 35, n (%) | |
| Antianginal | 4 (11) |
| Atrial hyperexcitability or AF | 21 (58) |
| Ventricular hyperexcitability | 5 (14) |
| Dilated heart disease | 11 (31) |
| LV obstruction | 3 (8) |
| Arterial hypertension | 2 (5) |
| 24h-Holter results | |
| Ventricular data | |
| Total PVCs | 11 (0-259), (min 0; max 12 809) |
| PVCs > 500/24 h, n (%) | 15 (15) |
| NSVT (<30 sec), n (%) | 9 (9); range, 4-121 PVCs |
| SVT (≥30 sec), n (%) | 0 (0) |
| Patients with VA, n (%) | 22 (22) |
| Total PVCs (n = 22) | 984 (452-4035) |
| PVC > 1000 (n = 22), n (%) | 11 (50) |
| PVC > 10 000 (n = 22), n (%) | 3 (13) |
| Polymorphic trait (≥2 families) (n = 22) | 18 (82) |
| Daytime predominance (n = 22) | 20 (91) |
| Ventricular hyperexcitability under beta-blocker (n = 22) | 8 (36) |
| Atrial data | |
| Total PACs | 35 (5-254), (min 0; max 24 270) |
| PACs > 500/24 h, n (%) | 17 (17) |
| Atrial fibrillation, n (%) | 3 (3) |
Ordinal data are reported as mean ± standard deviation when they have a normal distribution, or as median (Q1-Q3) when they do not have a normal distribution, and nominal data as absolute value and percentage.
AF, atrial fibrillation; LVH, left ventricular hypertrophy; NSVT, nonsustained ventricular tachycardia; SVT, sustained ventricular tachycardia.